clinical trial · NCT07681674
Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product
BicycleTx Limited·phase2·not yet recruiting·n = 16
Advanced Solid TumorsZelenectide pevedotinBT7480Nuzefatide pevedotin
brief summary
BiCAP-201 trial offers continued access to Bicycle investigational product treatments zelenectide pevedotin, nuzefatide pevedotin, and BT7480 for participants currently receiving and deriving clinical benefit from one of these treatments in a Bicycle Therapeutics-sponsored clinical trial. Bicycle Therapeutics will continue to monitor longer term safety of these treatments.
started
Aug 1, 2026
primary completion
May 30, 2030
completion
May 30, 2030
last updated
Jul 2, 2026
official title
Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product on a BicycleTx Limited-Sponsored Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol